Search This Blog

Monday, November 11, 2019

Warren’s health plan is big trouble for organized labor

Elizabeth Warren has a plan — to annoy union members who work for state and local governments. With her “Medicare for All” plan, the top-tier Democratic contender is revealing a tension in the neo-progressive movement.
Warren’s $20.5 trillion over a decade to pay for Medicare for All requires what she calls a “redirection” in funds: $6 trillion in “existing state- and local-government insurance spending.” Of this figure, $3.3 trillion goes for Medicaid, public insurance for poorer people.
But the other $2.7 trillion comes from the funds state and local governments “currently spend on employer contributions to private insurance premiums for their employees.”
Warren wants these governments to give this money to Washington instead. Teachers, firefighters, police officers and the like would be covered by a federal plan, not by the private plans their employers currently pay for.
This provision bares a weakness in Warren’s wonkiness. She is trying to fulfill her pledge not to raise taxes on middle-class Americans, but she can’t do it without expropriating the state and local taxes they already pay.
Yet Washington can’t just reach out and grab the money that state and local taxpayers provide to their governments. To gain their cooperation, Warren bets that state and local governments will voluntarily go along with this in exchange for future savings — that is, they’ll think that Washington can better manage health-care costs than they can.
The proposal is useful, then, in pointing out a fissure between insurgent politicians such as AOC, who style themselves as wanting universal, but more basic, rights for everyone, and the old-line public-sector unions that make up much of the Democratic voting base, who fight for select — and more expensive — perks for themselves.
Consider New York state’s own effort to create a similar single-payer health-care plan. Although Democrats control both lawmaking branches of government, the New York Health Act has languished, in part because of union opposition. The Municipal Labor Committee, a coalition of public-sector unions, worries that universal benefits won’t be as good for union members as the benefits they’ve bargained.
Or consider the local United Federation of Teachers’ deal with Mayor Bill de Blasio last year, awarding members a six-week family leave at 100 percent of pay.
This was unnecessary, as a matter of creating a basic safety net. The previous year, Gov. Andrew Cuomo had approved a more modest statewide family-leave program, funded by a payroll tax. A less powerful city union, DC-37, opted for the state program.
The UFT wasn’t fighting for a basic right then. If it were, it would stand in solidarity with DC-37 workers until the more generous benefit was universal. It was fighting for something special for its members, to keep them in the union.
Plus, public-sector unions regularly spurn the country’s most basic safety net, with many state and local workers exempt from paying Social Security taxes because they have superior pensions.
And though the federal government already has a near-universal Medicare program for retirees, New York City has amassed a more than $100 billion health-care liability for its own public-sector retirees. The state-subsidized Metropolitan Transportation Authority has amassed a similar $20 billion liability.
That’s because city and MTA workers and retirees expect more than what Washington offers.
To find out whether local unions support Medicare for All, or Medicare for All but Us, New York can perform an experiment right now. The MTA’s contract with the Transport Workers Union, which represents subway and bus workers, is up — and union chief Tony Utano has called for round-the-clock negotiations.
The MTA should ask the union to sign a provision to waive all health-care claims — eliminating that $20 billion future liability — should Congress pass a Warren-style plan. The city should ask its own unions to sign off on similar agreements as contracts expire.
There’s one good reason for state and local governments to prefer Warren’s plan. Cities like Chicago and states like New Jersey are broke, and have little hope of making good on their similar retiree-health-care obligations.
But if state and local governments want to trade their autonomy over a big portion of their tax dollars for the prospect of off-loading future health-care cost growth to Washington, they’ll first have to convince their own unions how broke they are.

Sunday, November 10, 2019

Addiction group makes real estate work

2191 Third Avenue
START Treatment & Recovery Centers has acquired a 15,765 s/f four-story building at 2191 Third Avenue in East Harlem, expanding and upgrading its clinic facilities for approximately 300 patients. START will house the new clinic on the ground floor and a portion of the second floor at 2191 Third Avenue.
It financed the acquisition though the sale of 2195 Third Avenue, a three story, 6,000 s/f building that previously housed its clinic, and 2193 Third Avenue, an adjacent 4,927 s/f vacant lot.
Ariel Property Advisors’ investment sales and capital services teams played a central role in both transactions.
Ariel’s investment sales team, which comprised of Michael A. Tortorici, Marko Agbaba and Sean O’Brien, participated in START’s purchase and also represented START in its sale of 2193-2195 Third Avenue.
Matthew Swerdlow of Ariel’s capital services team procured the financing for START’s purchase of the 2191 Third Avenue.
“Our newly renovated facility is bright, cheerful and modern with a comfortable waiting area, and since the clinical services are on the first floor, this new building accommodates the needs of our disabled patients,” said Lawrence S. Brown, Jr., CEO of START.
According to Dr. Brown, the new clinical site is a long-term investment in START’s future. East Harlem has experienced a tremendous surge in residential and commercial growth, as well as rezoning by the DeBlasio administration that will keep the area affordable and maintain the neighborhood’s culture.
START’s clinic is located across the street from Hunter College’s Silberman School of Social Work.
This is the second time START has used real estate to invest in its future.
This summer, START and its joint-venture partners Delshah Capital and OTL Enterprises launched the first phase of construction for 22 Chapel Street, a residential tower that will contain START’s headquarters and bring more affordable housing to Downtown Brooklyn.

Why Cigna, Humana, and UnitedHealth Group Soared in October

Cigna (NYSE:CI)Humana (NYSE:HUM), and UnitedHealth Group (NYSE:UNH) gained 17.6%, 15.1%, and 16.3% respectively in October, according to data from S&P Global Market Intelligence. That’s a huge move for some of America’s largest health insurers, and the largest one led the way. The big push for all three healthcare stocks began with UnitedHealth Group’s third-quarter earnings report in the middle of the month.

On Oct. 15, UnitedHealth Group beat Wall Street’s estimates on the top and bottom lines — and raised its earnings outlook for the rest of 2019. Instead of a range between $14.40 and $14.70 per share, adjusted earnings are expected to fall between $14.90 and $15 per share. The midpoint of that revised guidance range works out to a 16% year-over-year gain for UnitedHealth Group.
By market cap, Cigna and Humana are less than half the size of UnitedHealth Group, and there was more than enough enthusiasm for the industry’s largest player to spread around to its peers.
Humana stock has sustained a nice bump since UnitedHealth reported, even though Humana won’t report third-quarter results until Nov. 6.
Investors who pushed Cigna shares up in response to UnitedHealth’s earnings surprise weren’t disappointed. Cigna reported third-quarter adjusted earnings and revenue that surpassed consensus estimates on Oct. 31.
CI Chart
CI DATA BY YCHARTS.
Cigna’s largest operating segments — health services, and integrated medical — led the company forward. The company’s acquisition of Express Scripts, a pharmacy benefits manager and specialty pharmacy, is working out better than expected. Cigna folded the Express Scripts business into its health services segment near the end of 2018. During the first nine months of 2019, health services delivered top-line revenue that reached $70.9 billion, and a $3.6 billion operating profit.

We can probably expect the health services segment to contribute a great deal more to Cigna’s top and bottom lines in the fourth quarter, and into the years ahead. In 2020, the company expects its pharmacy services business to retain 97% of current customers, and to process between 25 million and 35 million more scripts. The midpoint of this expected range suggests the number of prescriptions processed will rise around 25% year over year, to a whopping 1.52 billion.
UnitedHealth Group’s health services segment, better known as its Optum segment, is also growing by leaps and bounds. Third-quarter OptumRx revenue rose 5.8% year over year to $18.5 billion, and OptumHealth revenue grew 34.4% year over year to $2.1 billion.
Optum is UnitedHealth’s fastest-growing segment; soon it will also be the most profitable. Savings from expanded local care delivery and behavioral health services have increased the segment’s operating margin, from 7.5% during the second quarter this year to 8.2% in the third.
If you’re going to go with one of these insurers, UnitedHealth Group is probably the best option. Its size, relative to competitors like Humana and Cigna, is a huge competitive advantage that’s driving annual earnings growth by double-digit percentages.
Despite the recent run-up, UnitedHealth shares have been trading at just 18.4 times trailing earnings. The average stock in the benchmark S&P 500 index trades at around 23.5 times trailing earnings; compared to that, this stock looks like a terrific bargain.

Concern over mixed results from Takeda’s dengue vaccine

Takeda’s dengue vaccine has met its target of protection against the disease in children – but there are already concerns about mixed results among different strains of the potentially deadly mosquito-borne disease.
There is a pressing need for a new dengue vaccine after a controversy blew up around Sanofi’s Dengvaxia, after the company acknowledged in certain cases it could increase the risk of severe diseases in people who had not been previously exposed.
This limited access to the first ever approved vaccine for the disease after deaths of children were reported in the Philippines, one of the first countries to receive the it.
Officials from Sanofi and the country’s health department could face criminal charges over irregularities in the immunisation programme based around Dengvaxia.
Based on results of the phase 3 TIDES study, it looks as if Takeda’s dengue vaccine codenamed TAK-003 is likely to be an improvement on Sanofi’s predecessor.
The trial met its primary endpoint of protection against dengue in children aged four to 16 years, with an overall efficacy of 80.2% in the 12 month period after the second dose, administered three months after the first shot.
Similar efficacy seen in those who were previously infected (82.2%) and those who had not been previously exposed (74.9%).
However Takeda’s statement summarising results pointed to “Serotype-specific efficacy” as all four strains of the disease were represented in the global trial.
Efficacy for serotype 1 was 73.7%, while for serotype 2 the figure was 97.7% – perhaps unsurprising given that the vaccine is based on a live-attenuated serotype 2 virus.
The figure for serotype 3 was 62.6% and there were too few cases of serotype 4 to give an accurate reading, Takeda said.
Dr Anna Durbin of the Johns Hopkins Bloomberg School of Public Health, who has helped develop a rival vaccine with the US National Institutes of Health, told Reuters there could be an “imbalance” in the vaccine, although she noted the overall efficacy was very good.
Dr Stephen Thomas, a dengue expert at the State University of New York Upstate Medical University, who has been a paid adviser for Takeda, Sanofi, and other pharmas, said results were “disappointing from the perspective that the field desires a vaccine with protective efficacy”.
However he noted that there was no indication of any harm coming from the vaccine.
Takeda plans filings in countries badly affected by dengue beginning in the second half of 2020, and further data are due to be published at the American Society of Tropical Medicine and Hygiene conference later this month.

FibroGen Q3 2019 Earnings Preview

FibroGen (NASDAQ:FGEN) is scheduled to announce Q3 earnings results on Monday, November 11th, after market close.
The consensus EPS Estimate is -$0.57 (-14.0% Y/Y) and the consensus Revenue Estimate is $31.61M (+9.0% Y/Y).
Over the last 1 year, FGEN has beaten EPS estimates 75% of the time and has beaten revenue estimates 50% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 3 upward revisions and 3 downward.

Earnings after Monday’s close

Biotech week ahead, Nov. 11

After the previous week’s strong gains, biotech stocks experienced a slight loss of momentum this week. The week saw a few clinical trial readouts and a slew of earnings reports from small- to mid-sized biotechs.
The FDA approved Sanofi SA’s SNY 0.84% Fluzone for older adults and Novartis AG’s NVS 1.55% Sandoz unit’s Neulasta biosimilar. REDHILL BIOPHAR/S ADR RDHL 1.79%‘s H. Pylori treatment was also OK’ed by the regulatory agency.
The following are the key catalytic events scheduled for the unfolding week.

Conferences

  • American Society of Nephrology, or ASN, Kidney Week 2019: Nov. 5-10 in Washington, D.C.
  • Society for Immunotherapy of Cancer, or SITC: Nov. 6-10 in National Harbor, Maryland
  • American Association for the Study of Liver Diseases, or AASLD, Liver Meeting: Nov. 8-12 in Boston, Massachusetts
  • American College of Rheumatology, or ACR, /ARP 2019 Annual Meeting: Nov. 8-13 in Atlanta, Georgia
  • 12th International Conference on Tissue Engineering & Regenerative Medicine: Nov. 11-12 in Madrid, Spain
  • 28th Annual Credit Suisse Healthcare Conference: Nov. 11-13 in Scottsdale, Arizona
  • 13th International Congress on Autoimmunity: Nov. 12-13 in London
  • 2019 Connective Tissue Oncology Society, or CTOS, Annual Meeting: Nov. 13-16 in Tokyo
  • European Congress on Nephrology & Urology: Nov.14-15 in Zagreb, Croatia
  • 13th International Conference on Alzheimer’s Disease & Dementia: Nov. 14-15 in Paris, France
  • 33rd European Ophthalmology Congress: Nov. 14-15 in Madrid
  • American Heart Association Scientific Sessions 2019: Nov. 16-18 in Philadelphia, Pennsylvania

PDUFA Dates

The FDA on Monday is expected to rule on Allergan plc’s AGN 1.44% NDA for Ubrogepant in the treatment of migraines.
Agile Therapeutics Inc AGRX 7.39% awaits word from the FDA on Saturday on its contraceptive patch Twirla. The odds of approval have increased since the Adcom gave a positive verdict in favor of approving the patch.
The stock, which lost about 67% in three sessions following the release of the briefing document Oct. 28, has added over 560% since the Adcom verdict.

Adcom Meeting

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet Thursday to discuss Amarin Corporation plc’s AMRN 4.3% sNDA for Vascepa for reducing the risk of cardiovascular events, as an adjunct to statin therapy in adult patients with elevated triglycerides levels and other risk factors for cardiovascular disease.

Clinical Trial Readouts

AASLD Presentations
Cocrystal Pharma Inc COCP 7.77%: new Phase 2a data for CC-31244 in hepatitis C (Sunday).
Mallinckrodt PLC MNK 0.48%: already-released Phase 3 data for terlipressin in hepatorenal syndrome Type 1 (Monday).
VBI Vaccines Inc VBIV 0.84%: already-released Phase 3 data for Sci-B-Vac, a hepatitis B vaccine (Monday).
Assembly Biosciences Inc ASMB 5.3%: Phase 2a data for ABI-H0731 for hepatitis B virus and Phase 1b data for ABI-H2158 also for hepatitis B virus (Monday).
Mirum Pharmaceuticals Inc MIRM 2.76%: Phase 2 data for Maralixibat in Algaille syndrome (Monday).
Eiger Biopharmaceuticals Inc EIGR 1.57%: Phase 2 data for pegylated interferon lambda + ritonavir-boosted lonafamib for hepatitis delta virus (Tuesday).
DURECT Corporation DRRX 2.15%: Phase 2a data for DUR-928 in alcoholic hepatitis (Tuesday).
CTOS Presentations
Deciphera Pharmaceuticals Inc DCPH 0.7%: initial Phase 1 data for DCC-3014 in solid tumors (Wednesday).
Oncternal Therapeutics Inc ONCT 0.52%: Phase 1 data for TK216 and vincristine in relapsed or refractory Ewing sarcoma (Saturday).
Adaptimmune Therapeutics PLC – ADR ADAP 1.74%: updated Phase 1 data for MAGE-A4 in solid tumors (Saturday).
ACR Presentations
Corbus Pharmaceuticals Holdings Inc CRBP 1.66%: Phase 2 open label data for lenabasum in systemic sclerosis (Sunday).
Kezar Life Sciences Inc KZR 1.03%: Updated Phase 1b data for KZR-616 in lupus (Tuesday).
Unity Biotechnology Inc UBX 4.97%: Phase 1b data for UBX0101 in osteoarthritis (Tuesday).

AHA Presentations

The Medicines Company MDCO 1.18% and Alnylam Pharmaceuticals, Inc. ALNY 1.63% – Detailed Phase 3 data for inclisiran from the ORION-10 study evaluating the asset for atherosclerosis cardiovascular disease (Saturday).
Caladrius Biosciences Inc CLBS 3.35%: Phase 2 data for CLBS16 in coronary microvascular dysfunction (Saturday).
Eidos Therapeutics Inc EIDX 4.62% and BridgeBio Pharma Inc BBIO 10.81%: Phase 2 data for AG10/BBP-265 in transthyretin amyloid cardiomyopathy, or ATTR-CM (Saturday).
Kiniksa Pharmaceuticals Ltd KNSA 4.57%: Phase 2 open label data for rilonacept in pericarditis (Saturday).

Earnings

The earnings list is not comprehensive. 
Monday, Nov. 11
Amicus Therapeutics, Inc. FOLD 0.22% (before the market open)
Foamix Pharmaceuticals Ltd FOMX 9.05% (after the market close)
ICU Medical, Incorporated ICUI 0.91% (after the market close)
Tuesday, Nov. 11
Akebia Therapeutics Inc AKBA 9.73% (before the market open)
Applied Genetic Technologies Corp AGTC 6.57% (after the market close)
Adamis Pharmaceuticals Corp ADMP 13.52% (after the market close)
Tetraphase Pharmaceuticals Inc TTPH 0.31% (after the market close)
Paratek Pharmaceuticals Inc PRTK 1.49% (after the market close)
Wednesday, Nov. 13
Alpine Immune Sciences Inc ALPN 1.07% (after the market close)
Biocept Inc BIOC 2.11% (after the market close)
DiaMedica Therapeutics Inc DMAC 14.45% (after the market close)
Gamida Cell Ltd GMDA 0.8% (after the market close)
Edap Tms SA EDAP 0.68% (after the market close)
Thursday, Nov. 14
Altimmune Inc ALT 0.54% (before the market open)
Vascular Biogenics Ltd VBLT 6.56% (before the market open)
Aytu Bioscience Inc AYTU 2.49% (after the market close)
Dare Bioscience Inc DARE 2.44% (after the market close)
Tricida Inc TCDA 0.76% (after the market close)

IPO Quiet Period Expiry

INNATE PHARMA S/S ADR IPHA 3.07%